

[Oseltamivir](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.4. Antiviral medicines 6.4.3. Other antivirals](#)

ATC codes: [J05AH02](#)

EMLc

Indication

Influenza due to identified seasonal influenza virus ICD11 code: [1E30](#)

INN

Oseltamivir

Medicine type

Chemical agent

List type

Complementary

Additional notes

Severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients.

Formulations

Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid (EMLc)

Oral > Solid: 30 mg capsule (as phosphate) ; 45 mg capsule (as phosphate) ; 75 mg capsule (as phosphate)

EML status history

First added in 2011 ([TRS 965](#))

Changed in 2013 ([TRS 985](#))

Changed in 2017 ([TRS 1006](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Oseltamivir](#)

DrugBank

[Oseltamivir](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of oseltamivir powder for oral liquid 6 mg/mL on the EMLc.